A Phase 2 Study Of Weekly Infusion Nab-Paclitaxel (Paclitaxel Protein-Bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma.

Trial Profile

A Phase 2 Study Of Weekly Infusion Nab-Paclitaxel (Paclitaxel Protein-Bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 30 Sep 2008 Actual start date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top